title: Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Martin F M
authors.initials: MF
authors.lastname: de Rooij
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Annemieke
authors.initials: A
authors.lastname: Kuil
authors.affiliation: Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.
authors.forename: Arnon P
authors.initials: AP
authors.lastname: Kater
authors.affiliation: Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.
authors.forename: Marie José
authors.initials: MJ
authors.lastname: Kersten
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.
authors.forename: Steven T
authors.initials: ST
authors.lastname: Pals
authors.affiliation: Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Lymphoma and Myeloma Center Amsterdam - LYMMCARE, Amsterdam, The Netherlands.
authors.forename: Marcel
authors.initials: M
authors.lastname: Spaargaren
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002448:Cell Adhesion / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D005434:Flow Cytometry; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010880:Piperidines; D051562:Proto-Oncogene Proteins c-bcr / Q000378:metabolism*; D011687:Purines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D052999:Quinazolinones / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D052999:Quinazolinones; C551803:ibrutinib; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr; D000225:Adenine; C552946:idelalisib
references.citation: Blood. 2014 May 29;123(22):3398-405
references.pmid: 24615778
references.citation: N Engl J Med. 2013 Aug 8;369(6):507-16
references.pmid: 23782157
references.citation: N Engl J Med. 2013 Jul 4;369(1):32-42
references.pmid: 23782158
references.citation: Blood. 2012 Mar 15;119(11):2590-4
references.pmid: 22279054
references.citation: Blood. 2014 May 29;123(22):3390-7
references.pmid: 24615777
references.citation: Blood. 2013 Oct 3;122(14):2412-24
references.pmid: 23940282
references.citation: N Engl J Med. 2014 Jun 12;370(24):2286-94
references.pmid: 24869598
references.citation: Blood. 2013 Mar 21;121(12):2274-84
references.pmid: 23341541
references.citation: N Engl J Med. 2014 Jul 17;371(3):213-23
references.pmid: 24881631